Korea South
AIGEN Sciences Inc., founded in 2021, is at the forefront of transforming drug discovery through its AI-Driven Drug Generation platform. Based in Korea South, the company operates within the Biotechnology and Pharmaceutical industries. AIGEN is set to revolutionize current practices by addressing inefficiencies and high costs, leveraging its platform to facilitate rapid and effective drug discovery.
The innovative AI platform offered by AIGEN Sciences distinguishes itself by enabling the discovery of high-potency drugs with specific cellular activity, while minimizing off-target effects and toxicity. This technological advancement positions AIGEN to significantly increase drug success rates during clinical trials.
Most recently, the company secured an Early VC investment in July 2025 from 효성벤처스 (Hyosung Ventures). This investment reflects confidence in AIGEN's potential to drive substantial advances in AI-based drug discovery, underscoring its influential role in reshaping the landscape of pharmaceutical innovation.
-logo.jpg){kind=logo}
